Which Will Trump: Healthcare M&A, or Earnings?
Insights - With three pieces of M&A news on Thursday morning, and a mixed bag of earnings from large bio/pharma companies so far this week, investors will see what they want … Continue Reading
Read nowAuthor Archives: Jake King
Does The Latest For Linzess Read Through to Synergy?
Research - Synergy Pharma (SGYP) fell briefly this morning when Phase V Research reported that Ironwood’s (IRWD) Linzess (linaclotide) is producing significant rates of adverse events in real world use, and that the drug may even be too dangerous to remain on the market.
Premium
Ariad’s Brigatinib May Finally Get Its Day
Research - Every stock has its day. Ariad Pharmaceuticals (ARIA) has had a few. From safety issues with its only marketed product Iclusig in 2014, that sent the stock reeling from $20 to $2, to repeat takeover rumors over the last few years that sent the stock soaring.
Premium
Oncology Conferences Approach: AACR in April
Research - With Allergan (AGN) and Pfizer (PFE) calling off plans to merge this week, the biotech sector rallied in a big way. Why? In part, Allergan … Continue Reading
Read now
With Actual Data, Vericel Loses Its Shine
Insights - Vericel Corp (VCEL) cratered on Monday with details from a phase 2b study of its ixmyelocel-T cell therapy for heart failure, presented at the American College … Continue Reading
Read now
Though Expected, Regeneron’s New Anti-Inflammatory Succeeds in Skin Disorder
Insights - On Friday, the companies announced success in two phase 3 studies of the IL-4/IL-13 antibody in AD, and now plan to file for approval later this year with the FDA.
Read now
Acadia Passes Last Hurdle Before FDA Approval Decision
Insights - Acadia Pharmaceuticals' (ACAD) pimavanserin received a positive opinion from a panel of outside experts to the U.S. FDA on Tuesday, a final step before the regulatory body decides on the drug's approval in Parkinson's Disease Psychosis this May.
Read now